In 2016 Sanofi only had two commercially significant marketed products for skin diseases – Allegra and Targocid – which generated $31m and $8m respectively.
These modest revenues meant the company commanded a market share of just 0.27%, which made it the 25th placed company in the therapy area.
Go deeper with GlobalData
However, between 2016 and 2023 Sanofi’s revenue from dermatology is forecast to increase at a compound annual growth rate (CAGR) of 83.6%, peaking at $2.8 billion in 2023.
This will make it the fourth largest company in the therapy area, with a market share of 10.3%.
Growth driven by Dupixent
In March 2017 Sanofi received FDA approval for Dupixent – the first biologic drug to treat moderate-to-severe atopic dermatitis.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataIt will be marketed by Sanofi and Regeneron, with the majority of the revenue going to Sanofi.
In 2017 Sanofi is forecast to generate $102 million from Dupixent, and between 2017 and 2023 this will increase at a CAGR of 154%, peaking at $2.75 billion in 2023.
With Sanofi’s and Regeneron’s 2023 Dupixent revenues combined, the drug will be the second most commercially successful product in dermatology, with an annual revenue of $3.6 billion, trailing behind only Novartis’s Cosentyx.
